BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 24218528)

  • 1. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial.
    Devos D; Moreau C; Maltête D; Lefaucheur R; Kreisler A; Eusebio A; Defer G; Ouk T; Azulay JP; Krystkowiak P; Witjas T; Delliaux M; Destée A; Duhamel A; Bordet R; Defebvre L; Dujardin K
    J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):668-74. PubMed ID: 24218528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease.
    Dujardin K; Devos D; Duhem S; Destée A; Marié RM; Durif F; Lacomblez L; Touchon J; Pollak P; Péré JJ
    J Neurol; 2006 Sep; 253(9):1154-9. PubMed ID: 16998649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholinesterase inhibitors for Parkinson's disease dementia.
    Maidment I; Fox C; Boustani M
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004747. PubMed ID: 16437494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: a retrospective analysis of a double-blind trial and an open-label extension.
    Oertel W; Poewe W; Wolters E; De Deyn PP; Emre M; Kirsch C; Hsu C; Tekin S; Lane R
    Drug Saf; 2008; 31(1):79-94. PubMed ID: 18095748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivastigmine: in Parkinson's disease dementia.
    Siddiqui MA; Wagstaff AJ
    CNS Drugs; 2006; 20(9):739-47; discussion 748-50. PubMed ID: 16953649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivastigmine for dementia associated with Parkinson's disease.
    Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R
    N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
    Poewe W; Wolters E; Emre M; Onofrj M; Hsu C; Tekin S; Lane R;
    Mov Disord; 2006 Apr; 21(4):456-61. PubMed ID: 16229010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ReSPonD trial--rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen.
    Henderson EJ; Lord SR; Close JC; Lawrence AD; Whone A; Ben-Shlomo Y
    BMC Neurol; 2013 Dec; 13():188. PubMed ID: 24299497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.
    Burn D; Emre M; McKeith I; De Deyn PP; Aarsland D; Hsu C; Lane R
    Mov Disord; 2006 Nov; 21(11):1899-907. PubMed ID: 16960863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
    Smith KM; Eyal E; Weintraub D;
    JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients.
    Barone P; Burn DJ; van Laar T; Hsu C; Poewe W; Lane RM
    Mov Disord; 2008 Aug; 23(11):1532-40. PubMed ID: 18581467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study.
    McKeith I; Del Ser T; Spano P; Emre M; Wesnes K; Anand R; Cicin-Sain A; Ferrara R; Spiegel R
    Lancet; 2000 Dec; 356(9247):2031-6. PubMed ID: 11145488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia.
    Gurevich TY; Shabtai H; Korczyn AD; Simon ES; Giladi N
    Mov Disord; 2006 Oct; 21(10):1663-6. PubMed ID: 16941467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living.
    Olin JT; Aarsland D; Meng X
    Dement Geriatr Cogn Disord; 2010; 29(6):510-5. PubMed ID: 20523050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
    Rösler M; Anand R; Cicin-Sain A; Gauthier S; Agid Y; Dal-Bianco P; Stähelin HB; Hartman R; Gharabawi M
    BMJ; 1999 Mar; 318(7184):633-8. PubMed ID: 10066203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
    Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
    Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
    Feldman HH; Ferris S; Winblad B; Sfikas N; Mancione L; He Y; Tekin S; Burns A; Cummings J; del Ser T; Inzitari D; Orgogozo JM; Sauer H; Scheltens P; Scarpini E; Herrmann N; Farlow M; Potkin S; Charles HC; Fox NC; Lane R
    Lancet Neurol; 2007 Jun; 6(6):501-12. PubMed ID: 17509485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial.
    Mowla A; Mosavinasab M; Haghshenas H; Borhani Haghighi A
    J Clin Psychopharmacol; 2007 Oct; 27(5):484-7. PubMed ID: 17873681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subthreshold depression in patients with Parkinson's disease and dementia--clinical and demographic correlates.
    Ehrt U; Brønnick K; De Deyn PP; Emre M; Tekin S; Lane R; Aarsland D
    Int J Geriatr Psychiatry; 2007 Oct; 22(10):980-5. PubMed ID: 17393542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of rivastigmine on neuropsychiatric symptoms in the early stages of Parkinson's disease: A systematic review.
    Reilly S; Dhaliwal S; Arshad U; Macerollo A; Husain N; Costa AD
    Eur J Neurol; 2024 Feb; 31(2):e16142. PubMed ID: 37975761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.